

Xuwei Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8005365/publications.pdf>

Version: 2024-02-01

8
papers

399
citations

1307594

7
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

881
citing authors

#	ARTICLE	IF	CITATIONS
1	SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. <i>Cell Reports</i> , 2019, 26, 65-78.e5.	6.4	146
2	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. <i>Cancer Cell</i> , 2016, 30, 485-498.	16.8	130
3	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathwayâ€ˆMutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. <i>Cancer Discovery</i> , 2021, 11, 3064-3089.	9.4	32
4	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	9.4	30
5	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. <i>Nature Cancer</i> , 2021, 2, 429-443.	13.2	29
6	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. <i>Oncogene</i> , 2019, 38, 47-59.	5.9	20
7	Global view of the RAF-MEK-ERK module and its immediate downstream effectors. <i>Scientific Reports</i> , 2019, 9, 10865.	3.3	12
8	Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6. , 2021, , .		0